Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 40,000 shares of the firm’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $8.91, for a total value of $356,400.00. Following the transaction, the insider now owns 245,746 shares in the company, valued at $2,189,596.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of NASDAQ ADRO opened at $8.05 on Friday. Aduro BioTech Inc has a 12-month low of $5.82 and a 12-month high of $14.05.
Aduro BioTech (NASDAQ:ADRO) last announced its earnings results on Thursday, March 1st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. The business had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $4.32 million. Aduro BioTech had a negative return on equity of 37.86% and a negative net margin of 532.88%. research analysts predict that Aduro BioTech Inc will post -1.29 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in ADRO. Bank of New York Mellon Corp boosted its position in Aduro BioTech by 23.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 175,642 shares of the biotechnology company’s stock valued at $1,871,000 after acquiring an additional 33,843 shares in the last quarter. SG Americas Securities LLC bought a new stake in Aduro BioTech during the 3rd quarter valued at $167,000. Trexquant Investment LP bought a new stake in Aduro BioTech during the 3rd quarter valued at $175,000. Wells Fargo & Company MN boosted its position in Aduro BioTech by 111.5% during the 3rd quarter. Wells Fargo & Company MN now owns 72,854 shares of the biotechnology company’s stock valued at $776,000 after acquiring an additional 38,415 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Aduro BioTech by 5.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 174,478 shares of the biotechnology company’s stock valued at $1,859,000 after acquiring an additional 9,140 shares in the last quarter. 44.94% of the stock is currently owned by institutional investors and hedge funds.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.